Diagnostic laboratory instruments and genomic sequencing
Strategic Profile
PerkinElmer positions itself as a critical partner for precision diagnostics and genomic workflows, with diversified exposure spanning genetic disorder detection, infectious disease testing, and oncology research applications. The company emphasizes innovation in protein-coupled receptor and next-generation DNA sequencing technologies to support drug discovery and clinical diagnostics workflows.
Cyborg Score Rationale
PerkinElmer delivered solid Q1 2026 fundamentals with $711M revenue and 53.7% year-over-year free cash flow growth, demonstrating operational strength. However, return on equity of 3.26% and elevated P/E multiple of 41–46x raise capital efficiency concerns, while 12-month stock performance down 21.5% signals sector headwinds despite market cap stability near $11B.
Top Insights
(May 2026) Q1 2026 earnings of $0.36 EPS and $711.12M revenue with 53.7% YoY free cash flow surge, indicating robust operational cash generation
Diagnostics segment includes genetic disorder screening (down syndrome, hypothyroidism, muscular dystrophy), infectious disease testing, and genomic workflows for oncology and drug discovery
Market cap approximately $11B–$14.5B as of June 2026 with ~109–125M shares outstanding; dividend yield 0.24%–0.28% with EUR 0.07 per share announced for Q3 2026
Elevated valuation multiples (P/E 41–46x) relative to historical norms and 52-week price range of $81–$118 reflect cautious investor sentiment and sector headwinds
Named Competitors
Next-Generation Sequencing — Leading NGS platforms for genomic analysis
Analytical Instruments — Separation and analytical laboratory instruments
Laboratory Solutions — Life sciences and diagnostics lab instrumentation
Clinical Diagnostics — Clinical diagnostic testing and insights
Recent Developments
(May 2026) Reported Q1 2026 earnings with $0.36 EPS and $711.12M revenue; free cash flow surged 53.69% YoY
(June 2026) Announced EUR 0.07 cash dividend with ex-date July 17, 2026
(April 2026) TTM earnings of £3.35B reported, indicating consistent earnings base
Open the full interactive PerkinElmer report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.